Pathological Regression by Angiotensin II Type 1 Receptor Blockade in Patients with Mesangial Proliferative Glomerulonephritis

• Published in: Hypertension research Vol. 31; no. 3; pp. 387 - 394
• Main Authors: Ohtake, Takayasu, Oka, Machiko, Maesato, Kyoko, Mano, Tsutomu, Ikee, Ryota, Moriya, Hidekazu, Kobayashi, Shuzo
• Format: Journal Article
• Language: English
• Published: England 01.03.2008
• Subjects: Adult; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Benzimidazoles - therapeutic use; Benzoates - therapeutic use; Biopsy; Creatinine - blood; Female; Fibrosis - drug therapy; Fibrosis - pathology; Glomerulonephritis, Membranoproliferative - blood; Glomerulonephritis, Membranoproliferative - drug therapy; Glomerulonephritis, Membranoproliferative - pathology; Humans; Immunoglobulin A - blood; Kidney Glomerulus - blood supply; Kidney Glomerulus - drug effects; Kidney Glomerulus - pathology; Losartan - therapeutic use; Male; Middle Aged; Receptor, Angiotensin, Type 1; Retrospective Studies; Tetrazoles - therapeutic use; Valine - analogs & derivatives; Valine - therapeutic use; Valsartan; Vasodilation

Although angiotensin II type 1 receptor blocker (ARB) therapy reduces proteinuria and retards the progression of renal injury in patients with glomerulonephritis, whether these drugs actually ameliorate pathological damages in human glomerulonephritis has not been determined. Fifteen patients with b...